ArticleBJC reports2025

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors.

Aurora Norman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.